KALA - kala pharmaceuticals

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

renna63

Nuovo Utente
Registrato
17/7/09
Messaggi
2.816
Punti reazioni
85
farmaco approvato alcuni giorni fa
U.S. FDA approves Kala Pharma'''s eye pain drug
cash x 1 anno
settembre pieno di appuntamenti interessanti e non ultimo grafico interessante (alla chiusura di ieri sera) con il titolo sopra tutte le mm veloci, sma 50 e kjiun sen, da seguire, primo target 14.75 e subito dopo sma 200

Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:

H.C. Wainwright 20th Annual Global Investment Conference
Date: Wednesday, September 5
Presentation Time: 3:00 p.m. ET
Location: New York, NY

2018 Wells Fargo Healthcare Conference
Date: Thursday, September 6
Presentation Time: 11:30 a.m. ET
Location: Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference
Date: Wednesday, September 12
Fireside Chat Time: 5:25 p.m. ET
Location: New York, NY
 

Allegati

  • KALA-Giornaliero.png
    KALA-Giornaliero.png
    68,5 KB · Visite: 511
farmaco approvato alcuni giorni fa
U.S. FDA approves Kala Pharma'''s eye pain drug
cash x 1 anno
settembre pieno di appuntamenti interessanti e non ultimo grafico interessante (alla chiusura di ieri sera) con il titolo sopra tutte le mm veloci, sma 50 e kjiun sen, da seguire, primo target 14.75 e subito dopo sma 200

Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:

H.C. Wainwright 20th Annual Global Investment Conference
Date: Wednesday, September 5
Presentation Time: 3:00 p.m. ET
Location: New York, NY

2018 Wells Fargo Healthcare Conference
Date: Thursday, September 6
Presentation Time: 11:30 a.m. ET
Location: Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference
Date: Wednesday, September 12
Fireside Chat Time: 5:25 p.m. ET
Location: New York, NY

entrato un po altino subito dopo approvazione a 12.99 graficamente mi piace.. ora hanno solo da guadagnare ;)
 
Qualcuno mi sa dire cosa potrebbe avere innescato questa discesa? farmaco approvato- cash ok- istituzionali al 90% qualcosa non mi torna... premetto di essere incastrato a 12.37 dopo aver mediato
 
Grafico abbastanza brutto
Downtrend che sembrava potesse cambiare da settembre ma non e successo.
Non la conosco ma vedo istituzionali massicci .
 
Grafico abbastanza brutto
Downtrend che sembrava potesse cambiare da settembre ma non e successo.
Non la conosco ma vedo istituzionali massicci .
Grazie Nean.. non sembra malaccio come azienda, tengo stretto
 
ma che succede????????:censored::wall::wall:
 
praticamente hanno fatto una bull trap con la rottura in agosto della sma 50, il titolo ha però piano piano perso forza e sotto la sma 50 a 12.60/65 andava messo uno stop loss e sotto il supporto a 11.81 tassativo andava stoppata, ora bisogna attendere che formi una base e dia almeno un segnale per provare a riprenderla.
 

Allegati

  • KALA-Giornaliero.png
    KALA-Giornaliero.png
    82 KB · Visite: 383
praticamente hanno fatto una bull trap con la rottura in agosto della sma 50, il titolo ha però piano piano perso forza e sotto la sma 50 a 12.60/65 andava messo uno stop loss e sotto il supporto a 11.81 tassativo andava stoppata, ora bisogna attendere che formi una base e dia almeno un segnale per provare a riprenderla.

grazie renna
 
il titolo è giovane quindi ho dato uno sguardo al 2018

gap 18,49/18,46 in corso

18,46 / 15,22 res 16,84
15,17 / 14,05
14,04 / 15,83
15,77 / 15,02
15,03 / 15,24
15,25 / 13,73
13,50 / 12,69
12,70 / 13,51
13,51 / 9,87 res 11,7

open ott 9,88

res w:eek: 10,3 sup 9

è certamente da approfondire e vedrò forse in seguito diciamo che il range lo vedo cosi come da grafo
 

Allegati

  • 1020.jpg
    1020.jpg
    109,9 KB · Visite: 17
il titolo è giovane quindi ho dato uno sguardo al 2018

gap 18,49/18,46 in corso

18,46 / 15,22 res 16,84
15,17 / 14,05
14,04 / 15,83
15,77 / 15,02
15,03 / 15,24
15,25 / 13,73
13,50 / 12,69
12,70 / 13,51
13,51 / 9,87 res 11,7

open ott 9,88

res w:eek: 10,3 sup 9

è certamente da approfondire e vedrò forse in seguito diciamo che il range lo vedo cosi come da grafo
grazie
 
offerta pubblica di azioni a poco più di 8 dollari, il titolo crolla ma si fa più interessante perchè alla fine dovrebbero avere 200 mil di cash e un farmaco approvato, qui sotto un riassunto e la metto in watch fino a quando avrà formato una base e avrà dato un segnale interessante.

Shares of Kala Pharmaceuticals (NASDAQ: KALA) fell nearly 18% today after the company announced the pricing of a common stock offering. The development-stage pharma will sell up to 8.625 million shares at a price of $8.25 per share, which is expected to generate up to $71.1 million in gross proceeds. Considering the offering will increase the number of shares outstanding by up to 35%, the stock's 18% plunge is relatively mild.
That could be because the share offering is the second infusion of cash announced in October. Kala Pharmaceuticals recently announced it will receive up to $110 million in debt financing from Athyrium Capital Management, LP. The first $75 million is already in the bank, while the remaining $35 million is payable upon certain milestones in the company's pipeline.
As of 11:44 a.m. EDT, the stock had settled to a 16.5% loss.



So what
The business is about to be swimming in cash. It exited June with $91 million in cash on hand. Throw in gross proceeds of about $71 million from the share offering and $75 million from the first tranche of the credit facility provided by Athyrium Capital Management, and Kala Pharmaceuticals should have around $200 million in cash at its disposal. It's going to need every penny for commercialization and development activities.
While Kala Pharmaceuticals stock has lost nearly 60% of its value since going public a little more than a year ago, the company recently received U.S. Food and Drug Administration marketing approval for Inveltys for the treatment of postoperative pain and inflammation following eye surgery. It's the first market validation for the company's novel technology platform, which is based on a simple idea.
All eye drugs must travel through the eye's mucus layer, which acts as a protective barrier against foreign objects. However, existing treatments are typically formulated as microparticles and, although small, they're actually too big to efficiently diffuse through the mucus barrier. That's why Kala Therapeutics is formulating its drugs as nanoparticles -- up to 1,000 times smaller than existing drug particles -- which should result in greater efficacy and require fewer applications for patients.
Case in point: Inveltys only needs to be applied twice per day, compared to four times daily for existing treatments. Then again, the platform has demonstrated mixed results.
Now what
The recent cash infusions will help Kala Pharmaceuticals hit the ground running in Inveltys commercialization efforts. Additionally, the company will be able to advance its dry-eye drug (currently in its third phase 3 trial with results expected at the end of 2019) and an early-stage asset for various retinal diseases. Considering the business lost more than $25 million from operations in the first half of 2018, it needed a lot of cash to keep moving forward. With finances taken care of, now the business needs to execute.
 
offerta pubblica di azioni a poco più di 8 dollari, il titolo crolla ma si fa più interessante perchè alla fine dovrebbero avere 200 mil di cash e un farmaco approvato, qui sotto un riassunto e la metto in watch fino a quando avrà formato una base e avrà dato un segnale interessante.

Shares of Kala Pharmaceuticals (NASDAQ: KALA) fell nearly 18% today after the company announced the pricing of a common stock offering. The development-stage pharma will sell up to 8.625 million shares at a price of $8.25 per share, which is expected to generate up to $71.1 million in gross proceeds. Considering the offering will increase the number of shares outstanding by up to 35%, the stock's 18% plunge is relatively mild.
That could be because the share offering is the second infusion of cash announced in October. Kala Pharmaceuticals recently announced it will receive up to $110 million in debt financing from Athyrium Capital Management, LP. The first $75 million is already in the bank, while the remaining $35 million is payable upon certain milestones in the company's pipeline.
As of 11:44 a.m. EDT, the stock had settled to a 16.5% loss.



So what
The business is about to be swimming in cash. It exited June with $91 million in cash on hand. Throw in gross proceeds of about $71 million from the share offering and $75 million from the first tranche of the credit facility provided by Athyrium Capital Management, and Kala Pharmaceuticals should have around $200 million in cash at its disposal. It's going to need every penny for commercialization and development activities.
While Kala Pharmaceuticals stock has lost nearly 60% of its value since going public a little more than a year ago, the company recently received U.S. Food and Drug Administration marketing approval for Inveltys for the treatment of postoperative pain and inflammation following eye surgery. It's the first market validation for the company's novel technology platform, which is based on a simple idea.
All eye drugs must travel through the eye's mucus layer, which acts as a protective barrier against foreign objects. However, existing treatments are typically formulated as microparticles and, although small, they're actually too big to efficiently diffuse through the mucus barrier. That's why Kala Therapeutics is formulating its drugs as nanoparticles -- up to 1,000 times smaller than existing drug particles -- which should result in greater efficacy and require fewer applications for patients.
Case in point: Inveltys only needs to be applied twice per day, compared to four times daily for existing treatments. Then again, the platform has demonstrated mixed results.
Now what
The recent cash infusions will help Kala Pharmaceuticals hit the ground running in Inveltys commercialization efforts. Additionally, the company will be able to advance its dry-eye drug (currently in its third phase 3 trial with results expected at the end of 2019) and an early-stage asset for various retinal diseases. Considering the business lost more than $25 million from operations in the first half of 2018, it needed a lot of cash to keep moving forward. With finances taken care of, now the business needs to execute.

Si interessante anche se ho cannato l'ingresso vabbè aspettiamo magari ci scappa un accordo
 
entrato con un cip in chiusura fuori da taverna... magari esplode ma buon gain...
 
Ciao viper69 :) faccio un agg a mio avviso bisogna tenere in considerazione questa candle res 10,3 / 9,88 e 8,81 non mi sono sb poi di molto :mad:
scrivo ciò per la proiezione che potrebbe innescarsi ma io il titolo non lo conosco ora con nuovi min diventa difficile prev il mrk ha risposto
al quesito la cassa non era abbastanza :confused:
 

Allegati

  • 9kala.jpg
    9kala.jpg
    101,3 KB · Visite: 16
preso un cippo qua
troppi acquisti di insiders, spero torni a 12
 
ha virato come da copione!!! istituzionali in massa con piccolissima parte retail.. per chi entra adesso un affare..:yes:
io sempre dentro con mediazioni varie a 10.82 :censored:
 
Indietro